The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Klaus Mross

Tumor Biology Center at the Albert-Ludwigs-University Freiburg

Germany

[email]@*.uni-freiburg.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Tumor Biology Center at the Albert-Ludwigs-University Freiburg, Germany. 2000 - 2011
  • Department of Medical Oncology, Tumor Biology Center at the Albert-Ludwigs-University, Breisacherstrasse 117, D-79106 Freiburg, Germany. 2010
  • Tumour Biology Center and Department of Radiology, Section MR-Development, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany. 2010

References

  1. Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. Mross, K., Frost, A., Scheulen, M.E., Krauss, J., Strumberg, D., Schultheiss, B., Fasol, U., Büchert, M., Krätzschmer, J., Delesen, H., Rajagopalan, P., Christensen, O. Vascular. Cell (2011) [Pubmed]
  2. A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment. Mross, K., Büchert, M., Fasol, U., Jaehde, U., Kanefendt, F., Strumberg, D., Arends, J., Hense, J., Moritz, B., Fischer, R., Scheulen, M.E. Int. J. Clin. Pharmacol. Ther (2011) [Pubmed]
  3. Clinical trials with anti-angiogenic agents in hematological malignancies. Medinger, M., Mross, K. J. Angiogenes. Res (2010) [Pubmed]
  4. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Mross, K., Stefanic, M., Gmehling, D., Frost, A., Baas, F., Unger, C., Strecker, R., Henning, J., Gaschler-Markefski, B., Stopfer, P., de Rossi, L., Kaiser, R. Clin. Cancer Res. (2010) [Pubmed]
  5. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. Mross, K., Fasol, U., Frost, A., Benkelmann, R., Kuhlmann, J., Büchert, M., Unger, C., Blum, H., Hennig, J., Milenkova, T.P., Tessier, J., Krebs, A.D., Ryan, A.J., Fischer, R. J. Angiogenes. Res (2009) [Pubmed]
  6. First-in-man and first-of-class-in-man clinical trials in oncology. Mross, K. Int. J. Clin. Pharmacol. Ther (2009) [Pubmed]
  7. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. Mross, K., Frost, A., Steinbild, S., Hedbom, S., Rentschler, J., Kaiser, R., Rouyrre, N., Trommeshauser, D., Hoesl, C.E., Munzert, G. J. Clin. Oncol. (2008) [Pubmed]
  8. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Mross, K., Steinbild, S., Baas, F., Gmehling, D., Radtke, M., Voliotis, D., Brendel, E., Christensen, O., Unger, C. Eur. J. Cancer (2007) [Pubmed]
  9. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing. Mross, K., Holländer, N., Frost, A., Unger, C., Ziroli, V., Massing, U. Onkologie (2006) [Pubmed]
  10. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Mross, K., Drevs, J., Müller, M., Medinger, M., Marmé, D., Hennig, J., Morgan, B., Lebwohl, D., Masson, E., Ho, Y.Y., Günther, C., Laurent, D., Unger, C. Eur. J. Cancer (2005) [Pubmed]
  11. Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications. Mross, K., Holländer, N., Unger, C., Massing, U. Int. J. Clin. Pharmacol. Ther (2005) [Pubmed]
  12. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR). Mross, K., Scheulen, M.E., Licht, T., Unger, C., Richly, H., Stern, A.C., Kutz, K., Camboni, M.G., Barbieri, P., Verdi, E., Vincenzi, B., Bernareggi, A. Anticancer. Drugs (2004) [Pubmed]
  13. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Mross, K., Niemann, B., Massing, U., Drevs, J., Unger, C., Bhamra, R., Swenson, C.E. Cancer Chemother. Pharmacol. (2004) [Pubmed]
  14. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Mross, K., Steinbild, S., Baas, F., Reil, M., Buss, P., Mersmann, S., Voliotis, D., Schwartz, B., Brendel, E. Int. J. Clin. Pharmacol. Ther (2003) [Pubmed]
  15. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial. Mross, K., Häring, B., Holländer, N., Mielke, S., Behringer, D., Massing, U., Unger, C. Onkologie (2002) [Pubmed]
  16. The pharmacokinetics of a 1-h paclitaxel infusion. Mross, K., Holländer, N., Hauns, B., Schumacher, M., Maier-Lenz, H. Cancer Chemother. Pharmacol. (2000) [Pubmed]
 
WikiGenes - Universities